Cargando…
Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cancer death in the United States, and also one of the major cancer-related deaths in Chinese. Androgen deprivation therapy (ADT) is the first line treatment for metastatic PCa. PCa ultimately relapse...
Autores principales: | Chou, Yu-Wei, Lin, Fen-Fen, Muniyan, Sakthivel, Lin, Frank C, Chen, Ching-Shih, Wang, Jue, Huang, Chao-Cheng, Lin, Ming-Fong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504398/ https://www.ncbi.nlm.nih.gov/pubmed/26185616 http://dx.doi.org/10.1186/s13578-015-0033-y |
Ejemplares similares
-
Human Prostatic Acid Phosphatase: Structure, Function and Regulation
por: Muniyan, Sakthivel, et al.
Publicado: (2013) -
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022) -
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy
por: Cao, Lin-Lin, et al.
Publicado: (2017) -
Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022) -
Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer
por: Mimeault, Murielle, et al.
Publicado: (2015)